Tag Archives: BSX

Healthcare Sector Roundup: Boston Scientific (NYSE:BSX), Bristol Myers Squibb (NYSE:BMY) – BMY, BSX, JNJ, ALXN, EXAS, BCRX

Posted on April 26, 2013 by Thomas Vedder

Investors responded positively to the healthcare stocks on Thursday. Key movement were observed in Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) and EXACT Sciences Corporation (NASDAQ:EXAS) on percentage gainers side while BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) was major percentage loser.

Boston Scientific Corporation (NYSE:BSX) …

Posted in Healthcare, Latest Headlines | Tagged Alexion Pharmaceuticals, ALXN, BCRX, BioCryst, BMY, Boston Scientific, Bristol-Myers Squibb, BSX, EXACT Sciences, EXAS, JNJ, Johnson, NASDAQ:ALXN, NASDAQ:BCRX, NASDAQ:EXAS, NYSE:BMY, NYSE:BSX, NYSE:JNJ | Comments Off

St. Jude Medical (NYSE:STJ) Profit Soars on Reduced Taxes – STJ, MDT, BSX, EW

Posted on April 18, 2013 by Thomas Vedder

St. Jude Medical, Inc (NYSE:STJ) announced a 4.7% boost in fiscal Q1 profit on lowered taxes, which counterbalance declining sales of its heart-shocking implants.

Medical device maker edged past Wall Street profit forecasts and reiterated its full-year earnings outlook.

Quarterly …

Posted in Latest Headlines, Services | Tagged Boston Scientific, BSX, Edwards Lifesciences, EW, MDT, Medtronic, NYSE:BSX, NYSE:EW, NYSE:MDT, NYSE:STJ, St. Jude Medical, STJ | Comments Off

Medtronic (NYSE:MDT) Profit Soars; Outshines Wall Street Forecasts

Posted on February 20, 2013 by Thomas Vedder

Medtronic, Inc (NYSE:MDT) announced higher quarterly earnings on Tuesday as sales moved up slightly.

The Minneapolis, Minnesota based company reported that its net earnings hiked to $988 million or 97 cents a share in the fiscal Q3 finished on Jan …

Posted in Healthcare, Main Post | Tagged Boston Scientific, BSX, Edwards Lifesciences, EW, MDT, Medtronic, NYSE:BSX, NYSE:EW, NYSE:MDT, NYSE:STJ, St. Jude Medical, STJ | Comments Off

Coventry Health Care (NYSE:CVH) Q4 Profit Outshines Wall Street Forecasts But Revenue Misses Estimates – CVH, AET, UNH, DNDN, CLDX, CLSN, PFE, BSX, ELN

Posted on February 6, 2013 by Geoff Noir

The Bethesda, Maryland-based Coventry Health Care, Inc (NYSE:CVH), which is being purchased by health insurer Aetna Inc (NYSE:AET), announced a profit for fiscal Q4 that hiked from previous year, showing strong operating margins amid lower costs and revenue expansion.

Managed …

Posted in Healthcare, Latest Headlines | Tagged AET, Aetna, Boston Scientific, BSX, Celldex Therapeutics, Celsion, CLDX, CLSN, Coventry Health Care, CVH, Dendreon, DNDN, Elan Corporation, ELN, NASDAQ:CLDX, NASDAQ:CLSN, NASDAQ:DNDN, NYSE:AET, NYSE:BSX, NYSE:CVH, NYSE:ELN, NYSE:PFE, NYSE:UNH, PFE, Pfizer, UNH, UnitedHealth | Comments Off

HUMHumana (NYSE:HUM) Declares fiscal Q4 Results; Earnings Hikes 3.5% – HUM, KERX, GILD, BSX, PPHM, MRK, HLF, AET, CI

Posted on February 4, 2013 by Geoff Noir

Humana Inc (NYSE:HUM) announced on Monday that fiscal Q4 earnings moved down 3.5 percent as higher coverage outlays masked firm’s revenue expansion from higher membership.

The health-care company done it’s almost $850 million purchase of Metropolitan Health Networks Inc in …

Posted in Healthcare, Latest Headlines | Tagged AET, Aetna, Boston Scientific, BSX, CI, Cigna, GILD, Gilead Sciences, Herbalife, HLF, HUM, Humana, KERX, Keryx Biopharmaceuticals, Merck, MRK, NASDAQ:GILD, NASDAQ:KERX, NASDAQ:PPHM, NYSE:AET, NYSE:BSX, NYSE:CI, NYSE:HLF, NYSE:HUM, NYSE:MRK, Peregrine Pharmaceuticals, PPHM | Comments Off

Aetna (NYSE:AET) Net Plunges 49% in Fiscal Q4 on Reimbursement Settlement – AET, BSX, ABIO, KERX, CLSN, GNBT, ABBV, CI, UNH

Posted on January 31, 2013 by Geoff Noir

Aetna Inc (NYSE:AET) reported that fiscal Q4 profit moved down 49% after the third-biggest United States health insurer decided to pay around $120 million to fix a court case regarding its payments to doctors.

The Hartford, Connecticut-based Aetna reported in …

Posted in Healthcare, Latest Headlines | Tagged ABBV, AbbVie, ABIO, AET, Aetna, ARCA biopharma, Boston Scientific, BSX, Celsion, CI, Cigna, CLSN, Generex Biotechnology, GNBT, KERX, Keryx Biopharmaceuticals, NASDAQ:ABIO, NASDAQ:CLSN, NASDAQ:KERX, NYSE:ABBV, NYSE:AET, NYSE:BSX, NYSE:CI, NYSE:UNH, OTC:GNBT, UNH, UnitedHealth | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.